A Double-blind, Randomized, 2-period, Placebo-controlled, Single-center, Crossover Study to Assess the Therapeutic Equivalence of the EMLA Current Reference Patch and the EMLA Test Patch in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
Price : $35 *
At a glance
- Drugs Lidocaine/prilocaine (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 13 Nov 2017 Status changed from active, no longer recruiting to completed.
- 03 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2017 Planned End Date changed from 24 Nov 2017 to 5 Dec 2017.